The partnership with Noom aims to cut costs by treating weight management as preventative healthcare. Nearly 2 million Highmark Health members are expected to be eligible for the programs.
Highmark Health, Noom to launch weight management partnership in 2026 Read More »
The company is dropping its social anxiety disorder program but will still test the molecule in post-traumatic stress disorder.
Neuphoria’s Social Anxiety Drug Flunks Late-Stage Trial Read More »
The public-private partnership aims to pump money into medical research as federal funds dry up. “We’re facing headwinds galore,” said Advocate’s chief innovation officer.
Advocate Health hopes new innovation center will boost medical research, training Read More »
The tool, which aims to help patients enroll in and maintain coverage, comes as healthcare braces for major cuts to the safety-net insurance program.
Medical billing firm Cedar launches Medicaid enrollment tool as cuts loom Read More »
Funds managed by Blackstone and TPG plan to acquire the medtech firm for up to $79 per share.
In this episode presented by Element Materials Technology, guests Dr. Jihye Jang-Lee and Dr. Khanh Courtney will explore how healthcare and pharmaceutical players are rethinking their strategies amid global supply chain disruption.
Cost Control to Capability Building: Rethinking Supply and Strategy in Pharma Read More »
The company’s technology, a modified herpes simplex virus used to deliver gene therapies, was given the FDA’s new designation based on its approved topical skin cream. What this will mean for Krystal’s still-in-development eye drop is unclear.
Krystal Biotech’s FDA Platform Designation Pushes Limits of the Award Read More »
The death occurred in a patient who had a complex medical background and who was being managed with several drugs, according to RBC Capital.
Ascendis Skids as FDA Detects Death in Patient on Yorvipath Read More »
In May, Summit released early data from the Phase III HARMONi study showing that while the PD-1/VEGF inhibitor resulted in significant progression-free survival improvements, it fell short of the overall survival bar.
Summit Eyes 2025 FDA Application for Ivonescimab Despite Overall Survival Miss Read More »
With data from the Phase III STELLAR-303 study in the books, Exelixis is plotting a 2025 regulatory application for zanzalintinib.
